MATINS Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) ·Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual · Patient recruitment for Part II in multiple cohorts progressing well    Company announcement, 01 June 2020 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS trial have been presented in a poster at the virtual ASCO20 (American Society of